Lessons from Canada's notice of compliance with conditions policy for the life-cycle regulation of drugs.

"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"S. K. Andersen et al., Conditional Approval of Cancer Drugs in Canada: Accountability and Impact on Public Funding , 26 Curr   Oncol e100–e105 (2019). S. K. Andersen et al., Conditional Approval of Cancer Drugs in Canada: Accountability And Impact on Public Funding , 26 Curr   Oncol e100–e105 (2019)."

"Health Canada Government of Canada, Public Release of Clinical Information: guidance document , (2019), https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/profile-public-release-clinical-information-guidance/document.html (accessed July 6, 2022). Health Canada, LARTRUVO (olaratumab) – New Clinical trial information important to prescribing decisions (2019) https://recalls-rappels.canada.ca/en/alert-recall/lartruvo-olaratumab-new-clinical-trialinformation- important-prescribing-decisions (accessed Jan. 30, 2023)."